The U.S. FDA approved a new chemotherapy as part of a multi-drug regimen for certain patients with two similar blood cancers. The U.S. Food and Drug Administration (FDA) approved asparaginase erwinia chrysanthemi (recombinant)-rywn (Rylaze)...
A reporter discusses the elevated risk for early-onset colorectal cancer in Black men, and more news of the week from Cancer Today.
Most scientists, regardless of field or career stage, have faced difficulties networking and disseminating their research in the past year, with many conferences and symposia canceled. The popularization of virtual meetings has helped researchers overcome this hurdle and keep in touch with their peers. However, early-career researchers—who...
A study found that the survival advantage for colon cancer patients in the U.S. Military Health System over the general population. The advantage was even greater for Black patients.
A study compares the benefits of fixed doses of immunotherapy compared to weight-based doses and more news of the week from the staff of Cancer Today magazine.
Scientists show that a form of DNA damage in colorectal cancer patients is associated with the consumption of red meat but not other foods or lifestyle factors.
The U.S. FDA has approved a molecularly targeted therapeutic to treat patients with advanced systemic mastocytosis. The U.S. Food and Drug Administration (FDA) approved the molecularly targeted therapeutic avapritinib (Ayvakit) to treat patients with...
They say age is just a number, but when it comes to cancer, getting older substantially increases your risk. Of the estimated 1.9 million cases of cancer diagnosed each year in the United States, approximately 80 percent are diagnosed in those over...
Triplet therapy shows promise for prostate cancer that was metastatic at diagnosis and more news of the week from the staff of Cancer Today magazine.
Most adults report inadequate knowledge of palliative care, according to a study published in the AACR journal Cancer Epidemiology, Biomarkers & Prevention.
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More